ERBB2 and breast carcinoma: Notably, the FMCp cell line presented a high sensitivity to neratinib (74.9% of cytotoxicity), suggesting its effect in other EGFR family members [20,56], and supporting the use of neratinib in HER2-negative breast cancer [57].